Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Lancet. Oncology|October 19, 2016
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyGlenwood Goss, Chun-Ming Tsai, Frances A Shepherd, et al.
Eclinicalmedicine|December 31, 2024
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialAbha A Gupta, Anna Tinker, Derek Jonker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid TumorsMartin Gutierrez, Victor Moreno, Kimberley M Heinhuis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Treatment of Pleural Mesothelioma: ASCO Guideline UpdateHedy L Kindler, Nofisat Ismaila, Lyudmila Bazhenova, et al.
JTO Clinical and Research Reports|October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 StudyQuincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancerCharles M Rudin, Christine L Hann, Edward B Garon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Pageof 6